Wall Street analyst estimates for Corcept Therapeutics Incorporated (CORT): consensus price target, buy/hold/sell recommendations and forecasts for revenue, EPS and EBITDA for the upcoming fiscal years.
Corcept Therapeutics Incorporated, founded in 1998 and headquartered in Menlo Park, California, is a pharmaceutical firm dedicated to the discovery, development, and commercialization of treatments for serious metabolic, oncological, and neuropsychiatric disorders across the United States. Its primary commercial offering is Korlym (mifepristone) tablets, an oral medication taken once daily.
Analyst Consensus
| Strong Buy | 0 |
| Buy | 14 |
| Hold | 9 |
| Sell | 3 |
| Strong Sell | 0 |
| Total analysts | 26 |
| Avg rating (1-5) | 0.42 |
Recent Earnings Surprises
| Date | EPS Actual | EPS Est. | vs Est. |
|---|---|---|---|
| 2026-11-04 | $0.81 | ||
| 2026-07-29 | $0.36 | $0.02 | +1383.3% |
| 2026-04-30 | $-0.30 | $-0.11 | -172.3% |
| 2026-02-24 | $0.20 | $0.33 | -39.4% |
| 2025-11-04 | $0.16 | $0.18 | -11.1% |
| 2025-07-31 | $0.29 | $0.23 | +26.1% |
| 2025-05-05 | $0.17 | $0.17 | +0.0% |
| 2025-02-26 | $0.26 | $0.37 | -29.7% |
Valuation Ratios
| P/E Ratio | 223.52 |
| Price / Book | 17.35 |
| EV / EBITDA | 433.39 |
| Dividend Yield | 0.00% |
Income Statement (10y)
| Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $81.3M | $159.2M | $251.2M | $306.5M | $353.9M | $366.0M | $401.9M | $482.4M | $675.0M | $761.4M |
| Cost of Revenue | $2.1M | $3.6M | $5.2M | $5.5M | $5.6M | $5.3M | $5.4M | $6.5M | $10.9M | $13.0M |
| Gross Profit | $79.3M | $155.6M | $246.0M | $301.0M | $348.3M | $360.7M | $396.5M | $475.9M | $664.2M | $748.4M |
| Research & Development | $23.8M | $40.4M | $75.2M | $89.0M | $114.8M | $113.9M | $131.0M | $184.4M | $246.9M | $254.9M |
| Selling, General & Admin | $45.2M | $62.4M | $81.3M | $100.4M | $105.3M | $122.4M | $152.8M | $184.3M | $280.3M | $448.7M |
| Operating Expenses | $69.1M | $102.8M | $156.5M | $189.4M | $220.1M | $236.2M | $283.8M | $368.6M | $527.2M | $703.6M |
| Operating Income | $10.2M | $52.9M | $89.5M | $111.6M | $128.2M | $124.5M | $112.6M | $107.3M | $137.0M | $44.8M |
| EBITDA | $10.3M | $53.0M | $89.7M | $113.8M | $130.4M | $128.0M | $117.5M | $125.6M | $162.8M | $68.4M |
| Interest Expense | $2.0M | $49,000 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Pre-tax Income | $8.1M | $52.8M | $92.2M | $116.7M | $131.6M | $125.0M | $116.2M | $124.6M | $161.5M | $66.5M |
| Income Tax | 0 | -$76.3M | $16.7M | $22.5M | $25.6M | $12.5M | $14.8M | $18.4M | $20.3M | -$33.2M |
| Net Income | $8.1M | $129.1M | $75.4M | $94.2M | $106.0M | $112.5M | $101.4M | $106.1M | $139.7M | $99.7M |
| EPS | $0.07 | $1.14 | $0.60 | $0.82 | $0.92 | $0.97 | $0.95 | $1.02 | $1.35 | $0.95 |
| EPS (Diluted) | $0.07 | $1.04 | $0.60 | $0.77 | $0.85 | $0.89 | $0.87 | $0.94 | $1.23 | $0.82 |
| Shares Outstanding (Diluted) | $116.1M | $124.5M | $126.7M | $122.6M | $124.2M | $126.0M | $116.0M | $111.7M | $113.5M | $120.0M |
Price
| Price | $122.03 |
| Market Cap | $13.2B |
| Exchange | NASDAQ |
| Country | US |
Related companies: ABVX · AXSM · CAI · CYTK · HALO · JAZZ · MRUS
Explore sector: Healthcare · Medical - Pharmaceuticals
More sections of CORT: Overview · Financials · Valuation · Statistics · Technical · Ownership · News · Events
Discover more: Weekly Radar: the S&P 500 through the Buffett and Lynch methods · Investment Academy — learn to analyze stocks